<div class="headers"><div>Figure 3 Proportion of all and very high-risk subjects achieving targets defined by European guidelines*. A. All Subjects. B. Very High-Risk Subjects with AVD. Error bars = standard error. * European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) [12]. † Triple combination includes LDL-C <1.8 mmol/L, non-HDL-C <2.6 mmol/L, and Apo B <0.8 g/L. A, atorvastatin (10, 20 or 40 mg); Apo, apolipoprotein; AVD, atherosclerotic vascular disease; E, ezetimibe 10 mg; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; border-bottom: 2px solid grey; text-align: left;'><p style="" class="">Figure 3 Proportion of all and very high-risk subjects achieving targets defined by European guidelines*. A. All Subjects. B. Very High-Risk Subjects with AVD. Error bars = standard error. * European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) [12]. † Triple combination includes LDL-C <1.8 mmol/L, non-HDL-C <2.6 mmol/L, and Apo B <0.8 g/L. A, atorvastatin (10, 20 or 40 mg); Apo, apolipoprotein; AVD, atherosclerotic vascular disease; E, ezetimibe 10 mg; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol.</p></td>
</tr>
</tbody>
</table>
